Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12ClNO2 |
| Molecular Weight | 261.704 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(Cl)C=CC=C1NC2=C(C=CC=C2)C(O)=O
InChI
InChIKey=YEZNLOUZAIOMLT-UHFFFAOYSA-N
InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. | 1981 |
|
| The use of combination therapies in the acute management of migraine. | 2006 Sep |
|
| Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. | 2007 |
|
| Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. | 2007 Apr 1 |
|
| Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. | 2007 Dec |
|
| Nonsteroidal anti-inflammatory drugs in cats: a review. | 2007 Jul |
|
| Acute migraine: Current treatment and emerging therapies. | 2007 Jun |
|
| Eicosanoid biosynthesis inhibitors increase the susceptibility of Lymantria dispar to nucleopolyhedrovirus LdMNPV. | 2007 Jun |
|
| Rapid method for the determination of non-steroidal anti-inflammatory drugs in animal tissue by liquid chromatography-mass spectrometry with ion-trap detector. | 2007 Mar 14 |
|
| Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. | 2007 Sep |
|
| Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. | 2007 Sep |
|
| Confirmatory identification of sixteen non-steroidal anti-inflammatory drug residues in raw milk by liquid chromatography coupled with ion trap mass spectrometry. | 2008 |
|
| In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. | 2008 Aug |
|
| Effects of meloxicam or tolfenamic acid administration on the pain and stress responses of Merino lambs to mulesing. | 2008 Aug |
|
| Current migraine management - patient acceptability and future approaches. | 2008 Dec |
|
| ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. | 2008 Dec |
|
| The effect of suspended particles coated by humic acid on the toxicity of pharmaceuticals, estrogens, and phenolic compounds. | 2008 Feb |
|
| catena-Poly[[bis-[2-(2,3-dimethyl-anilino)benzoato-κO]cadmium(II)]-di-μ-3-pyridylmethanol-κN:O;κO:N]. | 2008 Feb 6 |
|
| Effects of fenamate on inhibitory postsynaptic currents in Purkinje's cells. | 2008 May |
|
| Efficacy of tolfenamic acid and meloxicam in the control of postoperative pain following ovariohysterectomy in the cat. | 2008 Nov |
|
| Optimizing prophylactic treatment of migraine: Subtypes and patient matching. | 2008 Oct |
|
| Assessment of the duration of the pain response associated with lameness in dairy cows, and the influence of treatment. | 2008 Oct |
|
| Poloxamer 407 as a solubilising agent for tolfenamic acid and as a base for a gel formulation. | 2008 Sep 2 |
|
| Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. | 2009 |
|
| The relationship between diphenylamine structure and NSAIDs-induced hepatocytes injury. | 2009 Apr 25 |
|
| Polymer-induced heteronucleation of tolfenamic acid: structural investigation of a pentamorph. | 2009 Apr 8 |
|
| Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. | 2009 Dec 23 |
|
| Thermodynamic and structural study of tolfenamic acid polymorphs. | 2009 Dec 5 |
|
| Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. | 2009 Jul |
|
| Anti-inflammatory, antiproliferative, and radical-scavenging activities of tolfenamic acid and its metal complexes. | 2009 Jun |
|
| Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. | 2009 Mar |
|
| Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes. | 2009 Mar-Apr |
|
| The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. | 2009 May |
|
| Eicosanoids influence insect susceptibility to nucleopolyhedroviruses. | 2009 Nov |
|
| Development of a rapid, multi-class method for the confirmatory analysis of anti-inflammatory drugs in bovine milk using liquid chromatography tandem mass spectrometry. | 2009 Nov 13 |
|
| Confirmatory analysis of non-steroidal anti-inflammatory drugs in bovine milk by high-performance liquid chromatography with fluorescence detection. | 2010 Apr 23 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. | 2010 Feb 1 |
|
| Apoptotic Effect of Tolfenamic Acid in KB Human Oral Cancer Cells: Possible Involvement of the p38 MAPK Pathway. | 2010 Jul |
|
| Analytical strategy for the determination of non-steroidal anti-inflammatory drugs in plasma and improved analytical strategy for the determination of authorized and non-authorized non-steroidal anti-inflammatory drugs in milk by LC-MS/MS. | 2010 Jul |
|
| Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. | 2010 Jul 15 |
|
| Bismuth(III) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori. | 2010 Mar 21 |
|
| Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats. | 2010 May |
|
| Novel milk-based oral formulations: proof of concept. | 2010 May 10 |
|
| Postoperative analgesic efficacy of meloxicam compared to tolfenamic acid in cats undergoing orthopaedic surgery. | 2010 Oct |
|
| Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. | 2010 Sep 16 |
|
| Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. | 2010 Sep 29 |
|
| Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. | 2011 May 30 |
|
| Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. | 2013 Feb 25 |
|
| Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. | 2014 Apr |
Patents
Sample Use Guides
Take 200mg when the first symptoms of migraine appear. The treatment can be repeated once after 1-2 hours if a satisfactory response is not obtained.
Route of Administration:
Oral
Polymorphonuclear leukocytes were treated with tolfenamic acid at concentrations from 1 uM to 1000 uM and the compound inhibited LTB4-induced chemotaxis with IC50 value of 59 uM. Tolfenamic acid inhibited also FMLP-induced chemotaxis at the same concentration range (IC50 value was 46 uM).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/16/1614
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
||
|
WHO-VATC |
QM01AG02
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
||
|
WHO-ATC |
M01AG02
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
||
|
FDA ORPHAN DRUG |
517816
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
||
|
FDA ORPHAN DRUG |
517916
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2926
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
38377
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
8769
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
C009500
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
DTXSID1045409
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
3G943U18KM
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
13710-19-5
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
2698
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
32243
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
610479
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
m10943
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000077754
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
237-264-3
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL121626
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
SUB11155MIG
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
757873
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
Tolfenamic acid
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
C87328
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY | |||
|
DB09216
Created by
admin on Sat Dec 16 15:54:35 GMT 2023 , Edited by admin on Sat Dec 16 15:54:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
